JP2014502156A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502156A5
JP2014502156A5 JP2013541211A JP2013541211A JP2014502156A5 JP 2014502156 A5 JP2014502156 A5 JP 2014502156A5 JP 2013541211 A JP2013541211 A JP 2013541211A JP 2013541211 A JP2013541211 A JP 2013541211A JP 2014502156 A5 JP2014502156 A5 JP 2014502156A5
Authority
JP
Japan
Prior art keywords
peptide
peptide according
isolated
vector
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013541211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502156A (ja
JP6069212B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2011/050460 external-priority patent/WO2012072088A1/en
Publication of JP2014502156A publication Critical patent/JP2014502156A/ja
Publication of JP2014502156A5 publication Critical patent/JP2014502156A5/ja
Application granted granted Critical
Publication of JP6069212B2 publication Critical patent/JP6069212B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013541211A 2010-12-02 2011-12-02 ペプチド骨格設計 Expired - Fee Related JP6069212B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10193479.2 2010-12-02
EP10193479 2010-12-02
US201161475965P 2011-04-15 2011-04-15
US61/475,965 2011-04-15
PCT/DK2011/050460 WO2012072088A1 (en) 2010-12-02 2011-12-02 Peptide scaffold design

Publications (3)

Publication Number Publication Date
JP2014502156A JP2014502156A (ja) 2014-01-30
JP2014502156A5 true JP2014502156A5 (enExample) 2014-12-18
JP6069212B2 JP6069212B2 (ja) 2017-02-01

Family

ID=44022075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541211A Expired - Fee Related JP6069212B2 (ja) 2010-12-02 2011-12-02 ペプチド骨格設計

Country Status (10)

Country Link
US (2) US9550811B2 (enExample)
EP (1) EP2646459B1 (enExample)
JP (1) JP6069212B2 (enExample)
CN (1) CN103282375B (enExample)
AU (1) AU2011335551B2 (enExample)
CA (1) CA2819416C (enExample)
EA (1) EA025152B1 (enExample)
NZ (1) NZ611176A (enExample)
WO (1) WO2012072088A1 (enExample)
ZA (1) ZA201304017B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスBionor Immuno As 多量体ペプチド
US20150174235A1 (en) 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
KR20150018870A (ko) * 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
WO2016021605A1 (ja) * 2014-08-04 2016-02-11 日東電工株式会社 Ctlのアポトーシスを抑制するまたctlの誘導抑制を阻害するワクチン医薬組成物
CN107074910B (zh) * 2014-08-17 2022-02-18 塞里维瑞疗法公司 高级大分子转导域序列、编码其的多核苷酸及其用途
US20160060310A1 (en) 2014-08-27 2016-03-03 Daewoong Jo Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Hepatocellular Carcinoma Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Hepatocellular Carcinoma Compositions Comprising the Same
WO2017015064A1 (en) * 2015-07-20 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Detection phenotyping and quantitation of cells with multimeric binding reagent
US20170029798A1 (en) 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
WO2017026779A1 (en) 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Improved cell-permeable cre (icp-cre) recombinant protein and use thereof
EP3334755B1 (en) 2015-08-10 2020-04-08 Cellivery Therapeutics, Inc. Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
WO2017030323A1 (en) 2015-08-18 2017-02-23 Cellivery Therapeutics, Inc. Cell-permeable (cp)-δsocs3 recombinant protein and uses thereof
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
WO2018017442A1 (en) 2016-07-18 2018-01-25 President And Fellows Of Harvard College Methods and compositions relating to covalently circularized nanodiscs
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
US20220169680A1 (en) * 2018-11-02 2022-06-02 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Cell-penetrating peptide based on influenza virus m2 protein
EP3890783A1 (en) 2018-12-07 2021-10-13 Oxford University Innovation Limited Linkers
AU2023353862A1 (en) * 2022-09-30 2025-05-15 Capricor, Inc. Combination exosomal immunogenic compositions and methods
CN116077686B (zh) * 2022-12-15 2025-06-27 苏州智核生物医药科技有限公司 可酶切Linker及其用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4209215A1 (de) 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
JP3626996B2 (ja) 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム B型肝炎表面抗原および他の抗原からなる複合ワクチン
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
PT735893E (pt) 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
CA2175692A1 (en) 1993-11-04 1995-05-11 Geert Leroux-Roels Immunodominant human t-cell epitopes of hepatitis c virus
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
EP0754193B1 (en) 1994-04-08 2000-06-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Hepatitis c virus core peptide for stimulation of cytotoxic t lymphocytes and diagnosis of hcv exposure
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
CA2248937C (en) 1996-03-10 2011-10-11 Meiji Milk Products Co., Ltd. Peptide-based immunotherapeutic agent for treating allergic diseases
BR9708220A (pt) 1996-03-21 2000-01-04 Epimmune Inc Peptìdios de ligação hla-a2.1 e seus usos
JP3945822B2 (ja) 1996-05-24 2007-07-18 カイロン コーポレイション 複数エピトープ融合タンパク質
US6566330B1 (en) 1996-10-22 2003-05-20 Medical University Of South Carolina Foundation Research Development Positively charged non-natural amino acids, methods of making and using thereof in peptides
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
CA2377525A1 (en) 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
US20020076415A1 (en) 1999-12-14 2002-06-20 Jing-Hsiung Ou Hepatitis C virus gene products
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
JP2004522415A (ja) 2000-09-01 2004-07-29 エピミューン インコーポレーティッド Hla結合ペプチドおよびその使用方法
EP1195381A1 (de) 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
GB0026094D0 (en) 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
FR2824326B1 (fr) 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
AUPR593101A0 (en) 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
US7702465B2 (en) 2002-06-10 2010-04-20 Algonomics N.V. Method, computing routine, device for predicting properties of MHC/peptide complexes, and data and peptides produced therefrom
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
US20060217297A1 (en) * 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
EP1652858A1 (en) 2004-10-28 2006-05-03 Innogenetics N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
CA2610667A1 (en) 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
WO2008107400A1 (en) * 2007-03-02 2008-09-12 Genimmune N.V. Hcv polyepitope construct and uses thereof
AU2008269721B2 (en) 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
EP3327142A1 (en) 2007-07-13 2018-05-30 University of Pittsburgh- Of the Commonwealth System of Higher Education Virus derived antimicrobial peptides
US20100019186A1 (en) * 2008-07-25 2010-01-28 Eaton Corporation Engine valve assembly with valve can mountable to an engine cover
CN101412747B (zh) 2008-10-21 2011-04-20 中国药科大学 新型穿膜肽及其用途
US20110318830A1 (en) 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
US20120121537A1 (en) * 2009-01-12 2012-05-17 Chaomin Sun Methods and Compositions for Inhibiting Hepatitis C Virus Replication

Similar Documents

Publication Publication Date Title
JP2014502156A5 (enExample)
JP2014534202A5 (enExample)
JP2015524422A5 (enExample)
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2015501840A5 (enExample)
JP2014503206A5 (enExample)
JP2015521206A5 (enExample)
JP2014530010A5 (enExample)
JP2016534034A5 (enExample)
JP2014507144A5 (ja) 慢性b型肝炎感染症のための酵母系免疫療法組成物
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
JP2012501959A5 (enExample)
JP2013507907A5 (enExample)
JP2018148890A5 (enExample)
IL276210B2 (en) Mers-cov vaccine
RU2014135703A (ru) Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2, h2n2 и b
JP2015509707A5 (enExample)
JP2014507146A5 (enExample)
JP2015529678A5 (enExample)
JP2014509838A5 (enExample)
JP2015506705A5 (enExample)
JP2012515557A5 (enExample)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
JP2014519817A5 (enExample)